Arrowhead Pharmaceuticals (ARWR) reported fiscal Q2 earnings late Monday of $2.75 per diluted share, compared with a loss of $1.02 a year earlier.
Four analysts polled by FactSet expected a loss of $0.01.
Revenue for the quarter ended March 31 was $542.7 million. Analysts surveyed by FactSet expected $125.4 million.
Shares of the company were up more than 8% in after-hours activity.